Barclays PLC Has $339,000 Stock Holdings in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX)

Barclays PLC boosted its stake in shares of Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) by 201.9% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 78,151 shares of the company’s stock after purchasing an additional 52,265 shares during the period. Barclays PLC owned 0.14% of Black Diamond Therapeutics worth $339,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. Vestal Point Capital LP boosted its position in Black Diamond Therapeutics by 139.5% during the third quarter. Vestal Point Capital LP now owns 5,028,500 shares of the company’s stock valued at $21,874,000 after purchasing an additional 2,928,500 shares during the last quarter. Point72 Asset Management L.P. bought a new stake in Black Diamond Therapeutics in the third quarter valued at approximately $3,032,000. Affinity Asset Advisors LLC bought a new stake in Black Diamond Therapeutics in the second quarter valued at approximately $3,029,000. FMR LLC bought a new stake in Black Diamond Therapeutics in the third quarter valued at approximately $779,000. Finally, TD Asset Management Inc raised its stake in Black Diamond Therapeutics by 275.9% in the second quarter. TD Asset Management Inc now owns 266,312 shares of the company’s stock valued at $1,241,000 after buying an additional 195,464 shares during the period. 95.47% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms have issued reports on BDTX. Piper Sandler upped their price objective on Black Diamond Therapeutics from $12.00 to $15.00 and gave the company an “overweight” rating in a research note on Monday, September 23rd. Wedbush restated an “outperform” rating and issued a $16.00 price objective on shares of Black Diamond Therapeutics in a research note on Tuesday, October 8th. Finally, HC Wainwright restated a “buy” rating and issued a $11.00 price objective on shares of Black Diamond Therapeutics in a research note on Wednesday, November 6th.

Black Diamond Therapeutics Trading Up 2.8 %

Shares of NASDAQ BDTX opened at $2.20 on Friday. The firm has a market cap of $124.49 million, a P/E ratio of -1.65 and a beta of 2.47. Black Diamond Therapeutics, Inc. has a 1-year low of $2.08 and a 1-year high of $7.66. The business’s 50 day moving average is $2.58 and its 200-day moving average is $4.15.

Black Diamond Therapeutics (NASDAQ:BDTX) last announced its earnings results on Tuesday, November 5th. The company reported ($0.28) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.09. Analysts forecast that Black Diamond Therapeutics, Inc. will post -1.3 EPS for the current year.

Black Diamond Therapeutics Company Profile

Black Diamond Therapeutics, Inc, a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma.